Please ensure Javascript is enabled for purposes of website accessibility

Why NGM Biopharmaceuticals Dived by 41% on Monday

By Eric Volkman - May 24, 2021 at 6:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The results of a hepatitis drug candidate's clinical trial were not good.

What happened

For clinical-stage biotech companies, trial results are critical. On Monday, NGM Biopharmaceuticals (NGM 8.80%) reported very disappointing results from an investigative hepatitis drug and was summarily punished by investors, who drove the stock's price down by 41%.

So what

NGM's discouraging news concerned aldafermin, which was being evaluated for use in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), a form of fatty liver disease. 171 individuals took part in the study.

In the trial, the drug did not meet its primary endpoint of significant fibrosis improvement, although it did achieve statistical significance against its placebo on a number of secondary endpoints. These included the reduction of liver fat content.

"The lack of significant fibrosis improvement was unexpected given the consistency of histology findings previously seen with aldafermin in our adaptive four-cohort Phase 2 study," NGM quoted its CEO David Woodhouse as saying, in reference to an earlier-stage trial of the drug.

Medical professional mixing liquids in a lab.

Image source: Getty Images.

Now what

While investors understandably soured on NGM stock Monday, some observers continue to be bullish on the biotech. One is BMO Capital analyst Matthew Luchini, who is maintaining his overperform (read: buy) recommendation despite nearly halving his price target to $20 per share.

Characterizing the latest aldafermin study as "clearly disappointing," the analyst sees much potential in the biotech's pipeline, which is robust and filled mainly by cancer drugs. "We also see aldafermin's failure as a potential clearing event, allowing investors that avoided NGM due to NASH to revisit the story," he wrote in a research note.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NGM Biopharmaceuticals, Inc. Stock Quote
NGM Biopharmaceuticals, Inc.
$17.67 (8.80%) $1.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.